^
Association details:
| Biomarker: | EGFR E709Q |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | gefitinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer
Excerpt:
Of the 33 patients with tumors positive for mutant EGFR, 4 patients had disease progression within 2 months of gefitinib treatment. All these tumors were squamous cell carcinoma and the patterns of mutation were delA767_V769 (exon 20), A763V mutation (exon 20), L858R mutation (exon 21), and a double substitution mutation, G719S and L861Q, in exons 18 and 21.
DOI:
10.1158/1078-0432.CCR-04-1981
